olpasiran

Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
BioSpace
Mon, 08/28/23 - 12:02 pm
Amgen
cardiovascular disease
olpasiran
clinical trials
Could Amgen's Heart Disease Candidate Generate Billions in Sales?
Motley Fool
Sun, 12/11/22 - 01:26 pm
Amgen
heart disease
olpasiran
Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3
MedCity News
Wed, 11/9/22 - 11:30 pm
Amgen
Arrowhead Pharmaceuticals
olpasiran
heart disease
Amgen to test new way to lower heart risk with large drug trial
BioPharma Dive
Mon, 11/7/22 - 11:00 am
Amgen
clinical trials
heart disease
olpasiran
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
Pharmaforum
Wed, 06/1/22 - 09:33 am
Amgen
olpasiran
Novartis
clinical trials
cardiovascular disease